A Study of HDM2020 in Patients With Advanced Sq-NSCLC

NCT07638891 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Non-small Cell Lung Cancer(NSCLC)

Interventions

DRUG: HDM2020 (FGFR2b-ADC)

Sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.